OGT Grants DNA Sequence Variation Rights to Illumina
The rights to SNP genotyping remain valid for the lifetime of the patents.!--h2>
Illumina obtained permission to Oxford Gene Technology’s (OGT) patents for the detection of DNA sequence variations. The granted license will remain valid for the lifetime of the patents.
Under the license agreement, Illumina gained certain rights with respect to SNP genotyping. “OGT’s technology combined with Illumina’s BeadArray™ technology gives customers access to an extremely powerful SNP detection platform,” says Sue Sutton, vp, Licensing North America at OGT.